Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis

Abroad (travel likely)RecruitingPHASE2

Conditions

Primary Myelofibrosis (PMF) · Post Polycythemia Myelofibrosis (PPV MF) · Post Essential Thrombocythaemia Myelofibrosis (PET-MF)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Department of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong

    Contact: Study coordinator (Harinder Gill, MD) · gillhsh@hku.hk · 852 22555859
    Contact: Principal Investigator (Harinder Gill, MD)
Study leads
  • Harinder Gill, MD

    Principal Investigator

    The University of Hong Kong